🏢 官网IRRCELDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 04:10:07(美东 10-20 16:10)·⟳ 抓取 04:12:54回填·⚡ 决策 10-21 04:18:01 +7m54s·6.8 天前
AVITA Medical 仅预告将于11月5日盘后发布2026年三季报，无业绩数字或指引增量
这是典型的财报日期/电话会邀请公告：只说明未来何时披露三季报，没有任何实际财务结果、指引修正、订单、产品批准或融资信息；当前事件本身方向中性，不具备可交易预期差。
📄 原文RCEL↗ 原文
AVITA Medical to Announce Third Quarter 2026 Financial Results
VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or t…
不做 AVITA Medical, Inc.（RCEL.US）
常规财报日期公告，无收入、利润、指引、订单或产品进展增量，方向性edge不存在；应等待11月5日实际三季报。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
AVITA Medical 宣布三季报将于11月5日盘后发布并安排电话会，但未披露任何业绩数字或经营更新。该日程信息不产生方向或量级，回避，等待实际财报内容。
🔎 新鲜度:最早出现 2026-10-20 · 扩散 low · price-in 风险 low ↗
主要风险
- 真正的波动来自11月5日发布的实际三季报和指引，本公告本身不能提前推断利多或利空。
- 小盘医疗器械股可能受流动性和财报预期摆动影响，但那是后续财报事件风险，不是当前日程公告的交易依据。
先例如何影响了这次决策
对本次决策的影响:不进入交易；等待实际财报披露后再研究预期差、价格反应和可执行性。
方向:无可用于方向判断的同类价格先例；但事件文本自身已明确没有业绩数字，先例不会改变无增量事实的结论。
涨幅量级:不存在可校准涨幅或跌幅的基本面冲击。
形态:未评估；财报日期通知通常属于日历性公告，实际催化在11月5日财报。
原文全文
展开原文 · 2,583 字
VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Thursday, November 5, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 6, 2026, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent business highlights.
Third Quarter 2026 Webcast and Conference Call Information
To listen to the conference call webcast, please register and join using the following link:
https://edge.media-server.com/mmc/p/t9ebvg6s
.
To participate in the live earnings conference call, please register in advance to receive dial-in details and a personal PIN using the following link:
https://register-conf.media-server.com/register/BIc1fb986424694712b09792666b770137
.
For those unable to participate in the live broadcast, a replay will be available on the Events page of the Company’s investor relations website at:
https://ir.avitamedical.com/events-and-presentations
.
About AVITA Medical, Inc.
AVITA Medical
®
is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL
®
, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx
®
, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm
®
, a biosynthetic wound matrix.
In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO
®
are CE-marked in Europe, have TGA certification in Australia, and are listed with Medsafe in New Zealand; RECELL is PMDA-approved in Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
Third Quarter 2026 Webcast and Conference Call Information
To listen to the conference call webcast, please register and join using the following link:
https://edge.media-server.com/mmc/p/t9ebvg6s
.
To participate in the live earnings conference call, please register in advance to receive dial-in details and a personal PIN using the following link:
https://register-conf.media-server.com/register/BIc1fb986424694712b09792666b770137
.
For those unable to participate in the live broadcast, a replay will be available on the Events page of the Company’s investor relations website at:
https://ir.avitamedical.com/events-and-presentations
.
About AVITA Medical, Inc.
AVITA Medical
®
is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL
®
, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx
®
, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm
®
, a biosynthetic wound matrix.
In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO
®
are CE-marked in Europe, have TGA certification in Australia, and are listed with Medsafe in New Zealand; RECELL is PMDA-approved in Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
953e63bacb· 2026-10-21 04:18 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前